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Background Cardiac rehabilitation program (CRP) has been demonstrated to have beneficial effects on physical and
mental functioning as well as on mortality of patients with cardiovascular diseases, but its exact effect on lipid profile of
these patients is still vague. In this study we aimed to evaluate the effect of comprehensive CRP on lipid profile of the
Iranian population.
Design Self-controlled descriptive study.
Methods We evaluated 547 patients with documented coronary heart disease before and after a 24-session CRP between
1998 and 2003. Some of them received antilipid drugs.
Results Except for diastolic blood pressure, all other biophysical, biochemical [total cholesterol (TC), low-density
lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG)], functional, and psychosocial parameters had
significant response to CRP. We can attribute the normalization of lipid in these patients to CRP in combination with
medications 34.9% for TC, 17.7% for LDL, and 27.2% for TG (P<0.001 for all). Antilipid drugs had some more effect in
normalizing the TC (9.7%), LDL (1.8%), and TG (7.3%).
Conclusion Comprehensive CRP improves TC, TG, LDL, and HDL in Iranian patients with cardiovascular disease
even without antilipid drugs, and antilipid therapy can boost this effect. Eur J Cardiovasc Prev Rehabil 15:467–472 c 2008
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Introduction
Cardiovascular disease (CVD) is the leading cause of
death in Iran, which accounts for 46% of overall mortality
[1]. The rapid increase in coronary artery disease in Iran
and many other developing countries in the world is
associated with marked changes in life style regarding
diet and physical activity over the past two decades [2,3].
It has been demonstrated previously that Iran has some
remarkable features regarding CVD, as the Iranian
population has a greater risk for CVD than most other
populations, especially due to higher lipid risk factors [4].
An extensive literature on the effects of lipids on
atherosclerosis progression is available [5]. The impor-
tance of cholesterol lowering has been well documented
in the past both in primary and secondary prevention
strategies for reducing cardiovascular risk factors in some
studies [6].
Cardiac rehabilitation programs (CRPs), first developed
in the 1960s [7,8], have been shown to have beneficial
effects on mortality, exercise tolerance, functional capa-
city, lipid levels, blood pressure, symptoms of angina and
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dyspnea, weight loss, smoking behavior, stress level, and
psychosocial functioning [9–12]. However, there are
some controversies over the effect of CRP on different
types of serum lipids [13–16], and racial differences have
been mentioned in the degree of improvement of
patients’ lipid profile after CRP [17]. Considering the
selective effect of lipid-lowering drugs on different types
of serum lipids and the importance of lipid lowering in
the management of patients with cardiovascular diseases,
it seems vital to clarify the exact effect of CRP on
different types of serum lipids for better selection of
these drugs for patients completing a CRP. As up till now,
no investigation has been performed to evaluate changes
in lipid profile after CRP in the Iranian population, we
conducted a self-controlled observational study to eval-
uate the changes in lipid profile of the Iranian patients
completing a comprehensive CRP, whether receiving
antilipid medications or not.
Patients and methods
Study population and assessments
In a backward self-controlled observational study be-
tween 1998 and 2003, we evaluated 1220 patients with
coronary heart disease (CHD); they were referred to
cardiac rehabilitation (CR) department of the Isfahan
Cardiovascular Research Center by cardiology, interven-
tional and cardiac surgery departments. No selection
criteria existed, except for CR contraindication such as
unstable angina, acute phase of myocardial infarction
(MI), and unstable arrhythmia. Inclusion criteria con-
sisted completeness of 24 sessions of CRP irrespective of
antilipid medications use.
Patients had a history of MI, coronary artery bypass graft,
percutaneous coronary intervention, percutaneous trans-
luminal coronary angioplasty (PTCA) or CHD evidenced
by angiography. All of the patients with MI started
outpatient CR after 4 weeks of acute MI. In coronary
artery bypass graft patients, the duration between surgery
and the start of CR is 6–8 weeks, depending on the
surgeon’s opinion. In the percutaneous coronary inter-
vention patients CR should be started as soon as possible.
A checklist was completed for the patients at the time of
admission according to medical history and physical
examination by trained general practitioners, physiothera-
pists and nurses. It addressed demographic variables,
reason for referral to CR, the date of enrollment, CHD
risk factors, height, weight, waist and hip circumference,
systolic and diastolic blood pressures (SBP and DBP),
heart rate (HR), and drugs. Waist-to-hip ratio was
calculated according to National Heart, Lung, and Blood
Institute (NHLBI) recommendations [18].
To determine functional capacity, patients did a Naugh-
ton exercise test under the supervision of a cardiologist,
without withholding the patients’ medications [19]. In
addition, to determine left ventricular ejection fraction
(LVEF), a transthorasic echocardiography was done by
the cardiologists.
A blood sample was taken after 12–14 h of fasting to
measure fasting blood sugar, serum lipids including
triglyceride (TG), and total cholesterol (TC) using
enzymatic colorimetric methods. High-density lipopro-
tein (HDL) was determined after dextran sulphate-
magnesium chloride precipitation of non-HDL cholester-
ol; then, low-density lipoprotein (LDL) was calculated
according to Friedewald formula [20]. All tests were
measured at the beginning of the study.
Risk stratification of the patients (low, intermediate, and
high) was done by the cardiologists on the basis of
exercise test and LVEF [21].
In our study, medications which were prescribed to
patients were categorized to (i) directly affecting lipid
level [clofibrate, gemfibrazil, lovastatine, fluvastatine,
simvastatin, atrovastatin, nicotinic acid (niacin), choles-
teramin], (ii) indirectly affecting lipid levels (glucocorti-
coids, thiazide, b-blocker, valproate and related drugs,
garlic, estrogen and progesterone) [22,23], and (iii)
having no effect on lipids. Normal range of lipids is
considered as TG<150, LDL<100, and TC<200 for
both men and women.
Rehabilitation program and follow-up
The rehabilitation program comprised 24 exercise ses-
sions, scheduled over 8 weeks. Each session took 60–
90min, beginning with a 10–20min warm-up followed by
20–40min aerobic exercise, and was terminated with a
10min cool-down. In addition, there was a 20min
relaxation at the end of each session.
The intensity of the exercise was calculated according to
the determined risk, between 60 and 85% of the
maximum HR achieved on the exercise test [21]. The
exercise was done under electrocardiographic monitoring
if the patient was at high risk.
All patients received the psychological, nutritional, and
smoking cessation consultations. In addition, there were
weekly educational sessions during the 8 weeks of CRP,
both for patients and their families. It consisted of
explanations on cardiovascular diseases, introducing risk
factors, diagnoses and treatment approaches, medications
and their complications, stress reduction methods, and
advices on the healthy life style including smoking
cessation, nutrition, and physical activity.
For all patients who completed the whole CRP, the tests
were reconducted at the end of the study.
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Data processing, analysis and ethical consideration
Mean±SE, paired t-test, one-way analysis of variance,
Pearson and McNemar w2 were used in analysis. General
linear model was used for counterbalance the confounder
effect of quantitative dependent variables. Logistic
regression was utilized to adjust for the confounding
effects of qualitative variables. Stepwise multivariate
linear regression model was used with Pearson correlation
coefficient (r) to detect independent variables that can
predict changes in important dependent variables.
Differences and correlations with P<0.05 were consid-
ered statistically significant. SPSS 13 software (SPSS
Inc., Chicago, Illinois, USA) was used in analysis.
The study protocol was reviewed and approved by Isfahan
Cardiovascular Research Center Ethical Committee,
which is a member of the Office for Human Research
Protections, US, Department of Health and Human
Services, with the assurance number: FWA00008578.
Results
A total of 547 patients [400 (males (73.1%)] entered the
study. The remaining 653 patients (44.8%) dropped out
from CR. Table 1 shows their baseline characteristics.
Response to CRP according to physical, biochemical,
functional, and psychosocial parameters are mentioned in
Table 2. It showed that except for DBP, all other
parameters had significant improvement.
Level of TG was normalized (difference between
patients with abnormal levels at the beginning and end
of the study) in 44 patients (8.1%), LDL in 40 patients
(8.2%), and TC in 77 patients (14.1%). Percents of
patients with abnormal TG, LDL, and TC that have a
normal value at the end of follow-up were 50.2, 67.3 and
49.4%, respectively. However, there were some patients
with normal level of lipid profile initially who had an
abnormal value at the end of the study. This was 17.8, 9,
and 17.4% for TG, LDL, and TC, respectively. All of
these changes were significant (P<0.001).
Statins were mostly used in comparison with the other lipid-
lowering medications. [245 (44.8%) vs. 37 (6.8%) patients]
By adjusting for the effect of lipid-lowering medications,
CRP decreased the value of lipids significantly for TC, LDL,
and TG and increased the amount of HDL in patients who
had not used antilipid medications too (Table 3).
No significant difference between final value of lipids of
patients with and without using antilipid medications was
observed. Patients without antilipid drugs, however, had
lower HDL (P<0.001) and higher TC (P=0.01) before
CRP (Table 3).
We can attribute the normalization of lipid in these
patients to CRP in combination with medications 34.9%
for TC, 17.7% for LDL, and 27.2% for TG (P<0.001 for
all). Antilipid drugs had some more effects in normalizing
the TC (9.7%), LDL (1.8%), and TG (7.3%). Stepwise
linear regression showed significant models for predicting
Table 1 Basic characteristics of men and women patients referred
to CRP
Variables Description
Demographics
Age (year, mean±SE) 55.8±0.39
Job [no. (%)]
Self-employed 154 (28.2%)
Employed 127 (23.2%)
Retired 115 (21%)
Homemaker 124 (22.7%)
Worker 12 (2.2%)
Jobless 15 (2.7%)
Married [no. (%)] 533 (97.4%)
Educational level [no. (%)]
Illiterate 170 (31.4%)
Primary school 151 (27.9%)
Secondary school 137 (25.3%)
Master’s degree and higher 84 (15.4%)
Income (Toomans/month, mean±SE) 130533±5663
Reason for refer [no. (%)]
CABG 312 (57%)
MI 120 (22%)
PCI 52 (9.5%)
Abnormal angiography 11 (2%)
Others 52 (9.5%)
Risk factors [no. (%)]
Hypertensiona 175 (32.1%)
Dyslipidemiaa 286 (52.4%)
Family history 269 (49.2%)
Smoking 45 (8.2%)
Diabetesa 132 (24.1%)
History of obesity 218 (39.9%)
Present BMI (mean±SE) 27.2±0.16
Sedentary life style 196 (44.6%)
Risk stratification [no. (%)]
Low risk 350 (64%)
Intermediate 97 (17.7%)
High risk 100 (18.3%)
BMI, body mass index; CABG, coronary artery bypass graft; CRP, cardiac
rehabilitation program; MI, myocardial infarction; PCI, percutaneous coronary
interventions. aHistory of, or being on treatment for risk factor.
Table 2 Response to cardiac rehabilitation program
Variables
Before CRP
(mean±SE), N
After CRP
(mean±SE), N
Significant
value
Weight (kg) 73.1±0.47, 547 71.5±0.46, 542 <0.001
BMI (kg/m2) 27.2±0.16, 547 26.6±0.16, 542 <0.001
Waist circumference (cm) 99.3±0.44, 546 96.3±0.44, 536 <0.001
Hip circumference (cm) 104.2±0.32, 546 101.4±0.31, 536 <0.001
Waist-to-hip ratio 0.95±0.003, 546 0.95±0.003, 536 0.006
Serum lipoprotein levels
(mg/dl)
TC 225.2±2.1, 544 206.7±1.9, 547 <0.001
LDL 144.2±1.8, 504 127.5±1.6, 523 <0.001
HDL 39.8±0.38, 536 40.8±0.37, 543 0.014
TG 218±5.4, 545 192.5±3.98, 547 <0.001
FBS (mg/dl) 107.7±1.68, 545 104.2±1.29, 542 0.005
Functional capacity (Mets) 9±0.12, 543 11.2±0.13, 546 <0.001
LVEF (%) 50.3±0.51, 518 54.1±0.46, 447 <0.001
SBP (mmHg) 124.8±0.96, 547 121.9±0.83, 546 0.003
DBP (mmHg) 75.9±0.53, 547 75±0.48, 546 0.1
HR (per min) 83±0.78, 531 79.9±0.74, 526 <0.001
Depression score 4.3±0.19, 534 2.87±0.12, 534 <0.001
Anxiety score 17.1±0.59, 526 15.5±0.53, 526 <0.001
BMI, body mass index; CRP, cardiac rehabilitation program; DBP, diastolic blood
pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; HR, heart rate;
LDL, low-density lipoprotein; LVEF, left ventricle ejection fraction; SBP, systolic
blood pressure; TC, total cholesterol; TG, triglyceride.
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changes in LDL (P<0.001, R2=0.183), HDL (P<0.001,
R2= 0.224), TG (P<0.001, R2= 0.401), and TC
(P<0.001, R2= 0.343) (Table 4).
It showed that lower LDL, higher income, and lower age
would independently lead to lower final LDL after CRP.
Higher HDL, lower functional capacity, and not being a
smoker before CRP would lead to higher final HDL.
Patients with lower TG, lower body mass index (BMI), and
not being a smoker before CRP would have lower final TG.
Finally, if a person had lower TC and hip circumference and
higher functional capacity and LDL before CRP, he/she
would have lower TC after CRP (Table 4).
Discussion
In this study, we found that comprehensive CRP
(including physical activity, psychological, nutritional,
and smoking cessation consultations) and drug therapy
improved all assessed biophysical, biochemical, func-
tional, and psychosocial parameters including weight,
BMI, waist circumference, hip circumference, waist-to-
hip ratio, fasting blood glucose, functional capacity, LVEF,
SBP, HR, depression, and anxiety scores except DBP. In
this investigation, CRP and antilipid therapy showed to
improve TC, LDL, HDL, and TG. We also found that
improvement of HDL can be attributed to CRP alone
(without antilipid therapy).
Inability of CRP in improving DBP while reducing SBP in
a significant manner has been demonstrated in previous
trials [13]. Positive effect of CRP on body weights and
sizes has also been demonstrated by many authors
previously [17,24,25].
Exact effect of CRP on lipid profile of patients with
cardiovascular diseases is still a matter of debate. This
evaluation seems much more crucial in Iran. As it has
been reported that the Iranian population have much
higher CVD risk factors such as LDL, TC, and physical
inactivity in comparison with the US and Europe [26]. It
has also been reported that, based on the Rose Q and/or
ECG, the prevalence of CVD was significantly higher
among Iranian women than Iranian men [27]. In a
prospective study in which patients who received lipid-
lowering drugs were excluded, The HDL and LDL
fractions did not change significantly after completion of
a CRP including a combination of general dietary advice
and moderate physical exercise training [16], whereas
others have reported that CRP can improve LDL, HDL,
and TG in patients with CVD [15]. In other investiga-
tions, the increases in HDL after completion of CRP
have been demonstrated to be similar to those associated
with drug therapy [28]. In a systematic review and meta-
analysis of randomized controlled trials evaluating the
outcomes of exercise-based CRP, it has been illuminated
that CRP was associated with a significant reduction in
TC and TG levels whereas there seemed not to be a
significant difference in LDL and HDL cholesterol levels
after completion of CRP [13].
Within our literature review, there is a paucity of
assessments that have evaluated the simultaneous effect
of CRP and antilipid medications on patients’ lipid levels,
and instead have weighted their results according to the
effect of CRP and drugs separately. In an assessment,
measurement of lipid levels at enrollment in a CRP and
subsequently at regular intervals, with aggressive lipid-
lowering therapy, in consultation with the primary care
physician, has demonstrated to triple the use of drug
therapy and significantly reduced LDL levels [29]. In our
investigation, TC, TG, HDL, and LDL levels improved
significantly after comprehensive CRP and antilipid
therapy. Analysis of our data demonstrated that CRP
could reduce the levels of TC, TG, HDL, and LDL
significantly, even without using antilipid medication.
This was in line with an investigation showed that home-
based cardiac exercise program reduced TC, TG, HDL,
and LDL compared with the control group [30].
Comparison of the results of two groups (with and
without pharmacological therapy), showed that signifi-
Table 3 Comparison of response to cardiac rehabilitation program
in patients with and without (CRP only) antilipid drugs
Variables
Before CRP
(mean±SE), N
After CRP
(mean±SE), N
Significant
value
Serum lipoprotein levels in patients with antilipid drugs (mg/dl)
TC 230.9±3.2, 257 205.5 ±2.8, 257 <0.001
LDL 147.8±2.7, 231 125.9 ±2.4, 231 <0.001
HDL 41.2 ± .5, 256 41.4 ±0.5, 256 NS
TG 222.5 ±8.4, 258 187.7±5.9, 258 <0.001
Serum lipoprotein levels in patients without antilipid drugs (mg/dl)
TC 220.2 ±2.7, 288 207.9±2.4, 288 <0.001
LDL 141.4 ±2.4, 258 129.3 ±2.2, 258 <0.001
HDL 38.5±0.5, 277 40.2 ±0.5, 277 0.001
TG 213.9 ±7, 288 196.9±5.4, 288 0.002
CRP, cardiac rehabilitation program; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; TC, total cholesterol; TG, triglyceride.
Table 4 Multivariate stepwise linear regression analysis for
predicting final values of lipids
Dependent
variables
Independent
variables B
Significant
value
LDL TC before CRP 0.346 <0.001
Income –0.152 0.001
Age 0.096 0.028
HDL HDL before CRP 0.426 <0.001
Functional capacity before CRP –0.137 <0.001
Smokinga – 0.102 0.009
TG TG before CRP 0.584 <0.001
Smokinga 0.160 <0.001
BMI before CRP 0.099 0.005
Cholesterol TC before CRP 0.788 <0.001
Functional capacity before CRP –0.149 <0.001
LDL before CRP –0.331 <0.001
Hip circumference before CRP 0.134 0.001
aNonsmoker multiplied by 1 and smoker by 2. B, slope of linear regression;
BMI, body mass index; CRP, cardiac rehabilitation program; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
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cant increase of HDL is due to CRP alone and decrease of
TC, LDL, and TG was because of CRP with or without
antilipid drugs. The finding that antilipid therapy could
not improve HDL level, in this study, may be due to the
fact that in our study population, patients who received
antilipid therapy had higher basal levels of HDL. The
reason for the finding that antilipid therapy was not
effective enough to improve serum lipids (especially
LDL and TC) to the normal range may be low
compliance of our physicians and patients with antilipid
drugs [31]. It has been demonstrated in many investiga-
tions that acceptance of pharmacological treatment for
elevated lipids has been low. In the EuroAspire study, less
than 50% of patients received appropriate lipid-lowering
therapy after a cardiac event [32]. Under nonstudy
conditions, this percentage is probably even lower as in
the primary care settings [33], cardiology practices [34],
and academic centers [35] many patients with estab-
lished coronary artery disease are not treated with statins
or other lipid-lowering agents. Numerous attempts have
been made to improve compliance with the National
Cholesterol Education Program treatment guidelines
[36]. We suggest that a CRP should be considered as an
appropriate opportunity for improving patients’ compli-
ance with antilipid therapy. As education of the patients
is a main component of a comprehensive CRP, CRPs
should emphasize the need to adhere to the appropriate
medical regimen, in addition to the nonpharmacological
treatment modalities of CR, to achieve better risk-
reducing result.
In this investigation, regression models showed indepen-
dent factors for predicting the post-CRP values of lipid
profile. It showed that baseline level of lipids, income,
age, functional capacity, not being a smoker, BMI, and hip
circumference were the most important predictors.
Future studies may be able to show which of these
independent factors can constantly be entered in
regression models. These models can be used as practical
guidelines for the most useful interventions.
In our study, only 45% of patients who had entered the
CRP completed the course. For the remaining 55% of
patients, we could not check lipid profiles at the end of
the CRP duration which made us unable to evaluate the
isolated effect of antilipid drugs in our population. In this
investigation, we did not assess our patients’ compliance
with the medications that they were using during CRP
including antilipid drugs. We suggest that this is assessed
in future studies for evaluating the effect of CRP on
patients’ compliance with drugs and better clarification of
CRP outcomes. High rate of drop out of patients can be a
potential source of selection bias in our study.
Conclusion
This study showed the favorable effect of CRP on lipid
profile (including TC, TG, HDL, and LDL) of patients
with CVD. We also demonstrated that this effect
happened even without the use of lipid-lowering drugs.
Although, we suggest that for achieving the most
favorable impact on lipid levels in patients with CVD, a
multifactorial CRP that include exercise training, dietary
education, and psychological support and counseling
should also include educational sessions on the impor-
tance of pharmacological as well as nonpharmacological
treatments of serum lipids.
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